Data from the Phase 1b Study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) highlights preliminary efficacy in patients with the poorest prognosis, those with malignancy-associated HLH
SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that the company will present clinical data for its lead drug candidate, ELA026, in an oral session at the 40th Annual Meeting of the Histiocyte Society being held in Goa, India, on November 6-8.
The oral presentation will describe clinical data from the Phase 1b study of ELA026 for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, life-threatening hyperinflammatory disease for which there is no approved treatment. ELA026 is a first-in-class monoclonal antibody that targets signal regulatory protein (SIRP)-α/β1/γ on the cell surface of myeloid cells and T lymphocytes, the pathological immune cells that induce hyperinflammation in sHLH. The Phase 1b study is an open-label, single-arm, multi-center study designed to evaluate the safety and efficacy of ELA026, assess biomarkers, and identify a dose regimen for further evaluation in a Phase 2/3 study (NCT05416307).
Details of the oral presentation are as follows:
Title: ELA026 Targeting of SIRP(+) Immune Cells Results in a High Response Rate and Improved 2-Month Survival of Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Phase 1b Study
Presenter: Abhishek Maiti, MD, Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Session Name: Scientific Session I
Session Date and Time: Friday, November 8, 9:15 – 10:45 a.m. IST
About Secondary Hemophagocytic Lymphohistiocytosis
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening hyperinflammatory disease for which there is no approved treatment. It can be triggered by cancer, infection, autoimmune disease, or immunotherapy. sHLH is associated with a severe inflammatory response for which patients require immediate intervention. Without effective treatment, patients may experience multiple organ failure and death. sHLH has a high mortality rate during the first months of diagnosis, with malignancy-associated HLH (mHLH) patients having the poorest outcomes.
About Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies against novel targets for immunological diseases and cancer. The company’s lead product candidate, ELA026, is a first-in-class monoclonal antibody that targets SIRP on the cell surface of myeloid cells and T lymphocytes, and selectively depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, life-threatening hyperinflammatory condition for which there is no approved treatment, as well as additional disease indications. For more information, please visit www.electra-therapeutics.com and follow us on LinkedIn.
Media Contact:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
